Synopsis
Synopsis
0
VMF
0
Australia
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Gs 4071
2. Gs 4104
3. Gs-4071
4. Gs-4104
5. Gs4071
6. Gs4104
7. Oseltamivir
8. Tamiflu
1. 204255-11-8
2. Tamiflu
3. Oseltamivir (phosphate)
4. Oseltamir Phosphate
5. Agucort
6. Ro 64-0796/002
7. Aseltamivir Phosphate
8. Gs 4104
9. Oseltamivir (as Phosphate)
10. 4a3o49ngez
11. Ethyl (3r,4r,5s)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate Phosphate
12. Chebi:7799
13. Ethyl (3r,4r,5s)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate Phosphate (1:1)
14. (3r,4r,5s)-ethyl 4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylate Phosphate
15. (3r-(3alpha,4beta,5alpha))-ethyl 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate Phosphate (1:1)
16. Ro-64-0796-002
17. Ro-64-0796/002
18. 1-cyclohexene-1-carboxylic Acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, Ethyl Ester, (3r,4r,5s)-, Phosphate (1:1)
19. Phosphoric Acid Ethyl (3r,4r,5s)-5-amino-4-acetamido-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate
20. Oseltamivir Phosphate [usan]
21. Unii-4a3o49ngez
22. Sr-05000001499
23. Mfcd08059548
24. Ebilfumin (tn)
25. Oseltamivir Phosphate [usan:usp]
26. Ethyl (3r,4r,5s)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate;phosphoric Acid
27. Tamiflu (tn)
28. Oseltamiviri Phosphas
29. Gs 4104 Phosphate
30. Schembl8730
31. (3r-(3alpha,4beta,5alpha)-ethyl 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate Phosphate (1:1)
32. Mls006011559
33. Amy583
34. Chembl1200340
35. Dtxsid0044230
36. Oseltamivir Phosphate (jan/usp)
37. Bcpp000138
38. Oseltamivir Phosphate [mi]
39. Oseltamivir Phosphate [jan]
40. Act03369
41. Oseltamivir Phosphate [vandf]
42. S2597
43. Oseltamivir Phosphate [mart.]
44. Akos015896056
45. Oseltamivir Phosphate [usp-rs]
46. Oseltamivir Phosphate [who-dd]
47. Oseltamivir Phosphate [who-ip]
48. Bcp9001033
49. Ccg-230250
50. Cs-0871
51. Ks-1184
52. Nsc 758897
53. Oseltamivir Phosphate, >=98% (hplc)
54. 1-cyclohexene-1-carboxylic Acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, Ethyl Ester, (3r-(3alpha,4beta,5alpha)-, Phosphate (1:1)
55. Ac-25911
56. Bo164181
57. Ethyl (3r,4r,5s)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate, Phosphate (1:1)
58. Hy-17016
59. Smr004703323
60. Oseltamivir Phosphate [orange Book]
61. Oseltamivir Phosphate [ep Monograph]
62. Oseltamivir Phosphate [usp Impurity]
63. Oseltamivir Phosphate [usp Monograph]
64. Oseltamiviri Phosphas [who-ip Latin]
65. Gs-4104/002
66. C08093
67. D00900
68. 255o118
69. Sr-05000001960
70. J-013302
71. J-523838
72. Sr-05000001499-2
73. Sr-05000001960-1
74. Q27107588
75. Z1550675456
76. Benzofuran-3-yl-(3-boc-amino-azetidin-1-yl)-aceticacid
77. Oseltamivir Phosphate, United States Pharmacopeia (usp) Reference Standard
78. Oseltamivir Phosphate (impurity B Free), European Pharmacopoeia (ep) Reference Standard
79. Oseltamivir Phosphate, Pharmaceutical Secondary Standard; Certified Reference Material
80. (3r,4r,5s)-4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic Acid Ethyl Ester Phosphate
81. (3r,4r,5s)-4-acetylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic Acid Ethyl Ester Phosphate
82. (3r,4r,5s)-4-acetylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic Acid Ethyl Ester Phosphoric Acid Salt
83. (3r,5s)-ethyl 4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylate Phosphate;osteltamivir Phosphate
84. (3r-(3.alpha.,4.beta.,5.alpha.))-ethyl 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate Phosphate (1:1)
85. Ethyl (3r,4r,5s)-5-amino-4-acetamido-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate; Phosphoric Acid
86. Ethyl-(3r,4r,5s)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate Phosphate
| Molecular Weight | 410.40 g/mol |
|---|---|
| Molecular Formula | C16H31N2O8P |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 8 |
| Exact Mass | 410.18180295 g/mol |
| Monoisotopic Mass | 410.18180295 g/mol |
| Topological Polar Surface Area | 168 Ų |
| Heavy Atom Count | 27 |
| Formal Charge | 0 |
| Complexity | 468 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Oseltamivir phosphate |
| PubMed Health | Oseltamivir (By mouth) |
| Drug Classes | Antiviral |
| Drug Label | TAMIFLU (oseltamivir phosphate) is available as capsules containing 30 mg, 45 mg, or 75 mg oseltamivir for oral use, in the form of oseltamivir phosphate, and as a powder for oral suspension, which when constituted with water as directed contains 6 m... |
| Active Ingredient | Oseltamivir phosphate |
| Dosage Form | Capsule |
| Route | oral |
| Strength | 30mg |
| Market Status | Tentative Approval |
| Company | Natco Pharma |
| 2 of 4 | |
|---|---|
| Drug Name | Tamiflu |
| Drug Label | TAMIFLU (oseltamivir phosphate) is available as capsules containing 30 mg, 45 mg, or 75 mg oseltamivir for oral use, in the form of oseltamivir phosphate, and as a powder for oral suspension, which when constituted with water as directed contains 6 m... |
| Active Ingredient | Oseltamivir phosphate |
| Dosage Form | Capsule; For suspension |
| Route | Oral |
| Strength | eq 75mg base; eq 6mg base/ml; eq 30mg base; eq 45mg base |
| Market Status | Prescription |
| Company | Roche |
| 3 of 4 | |
|---|---|
| Drug Name | Oseltamivir phosphate |
| PubMed Health | Oseltamivir (By mouth) |
| Drug Classes | Antiviral |
| Drug Label | TAMIFLU (oseltamivir phosphate) is available as capsules containing 30 mg, 45 mg, or 75 mg oseltamivir for oral use, in the form of oseltamivir phosphate, and as a powder for oral suspension, which when constituted with water as directed contains 6 m... |
| Active Ingredient | Oseltamivir phosphate |
| Dosage Form | Capsule |
| Route | oral |
| Strength | 30mg |
| Market Status | Tentative Approval |
| Company | Natco Pharma |
| 4 of 4 | |
|---|---|
| Drug Name | Tamiflu |
| Drug Label | TAMIFLU (oseltamivir phosphate) is available as capsules containing 30 mg, 45 mg, or 75 mg oseltamivir for oral use, in the form of oseltamivir phosphate, and as a powder for oral suspension, which when constituted with water as directed contains 6 m... |
| Active Ingredient | Oseltamivir phosphate |
| Dosage Form | Capsule; For suspension |
| Route | Oral |
| Strength | eq 75mg base; eq 6mg base/ml; eq 30mg base; eq 45mg base |
| Market Status | Prescription |
| Company | Roche |
* Treatment of influenza:
Tamiflu is indicated in adults and children including full term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms. Prevention of influenza
- Post-exposure prevention in individuals one year of age or older following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community.
- The appropriate use of Tamiflu for prevention of influenza should be determined on a case-by-case basis by the circumstances and the population requiring protection. In exceptional situations (e. g. in case of a mismatch between the circulating and vaccine virus strains, and a pandemic situation) seasonal prevention could be considered in individuals one year of age or older.
- Tamiflu is indicated for post-exposure prevention of influenza in infants less than 1 year of age during a pandemic-influenza outbreak.
Tamiflu is not a substitute for influenza vaccination.
The use of antivirals for the treatment and prevention of influenza should be determined on the basis of official recommendations. Decisions regarding the use of oseltamivir for treatment and prophylaxis should take into consideration what is known about the characteristics of the circulating influenza viruses, available information on influenza drug susceptibility patterns for each season and the impact of the disease in different geographical areas and patient populations.
Treatment and prevention of influenza
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
Antiviral Agents
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)
J05AH02
Synnat Pharma is one of the leading active pharmaceutical ingredients and intermediates manufacturers.
Date of Issue : 2024-05-22
Valid Till : 2027-02-07
Written Confirmation Number : WC-0301
Address of the Firm :
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Gonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
GDUFA
DMF Review : Reviewed
Rev. Date : 2021-03-01
Pay. Date : 2020-09-28
DMF Number : 33907
Submission : 2020-04-30
Status : Active
Type : II
Registrant Name : Sungwoo Biopharm Co., Ltd.
Registration Date : 2021-02-05
Registration Number : 20210205-209-J-833
Manufacturer Name : Sinopep-Allsino Biopharmaceutical Co., Ltd.
Manufacturer Address : No. 28, Linpu Road, Economic & Technological Development Zone, Lianyungang, Jiangsu Province, 222000, China

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36256
Submission : 2021-09-22
Status : Active
Type : II

GDUFA
DMF Review : Reviewed
Rev. Date : 2023-10-12
Pay. Date : 2023-09-27
DMF Number : 38716
Submission : 2023-08-30
Status : Active
Type : II
Registrant Name : Iksoo Pharmaceutical Co., Ltd.
Registration Date : 2025-04-21
Registration Number : 20250421-209-J-1848
Manufacturer Name : Ruyuan HEC Pharma Co., Ltd.
Manufacturer Address : Xiaba Development Zone, Ruyuan County, Shaoguan City, 512721, Guangdong Province, China

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
GDUFA
DMF Review : Complete
Rev. Date : 2021-11-19
Pay. Date : 2021-09-30
DMF Number : 21557
Submission : 2008-05-29
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2016-07-19
Pay. Date : 2016-05-03
DMF Number : 30412
Submission : 2016-03-16
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2024-08-09
Pay. Date : 2024-07-21
DMF Number : 34775
Submission : 2020-04-01
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2021-03-01
Pay. Date : 2020-09-28
DMF Number : 33907
Submission : 2020-04-30
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2020-01-24
Pay. Date : 2019-11-13
DMF Number : 33767
Submission : 2020-01-10
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2016-07-06
Pay. Date : 2016-04-08
DMF Number : 30253
Submission : 2016-04-13
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2014-03-25
Pay. Date : 2013-09-23
DMF Number : 27533
Submission : 2013-09-29
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2014-05-16
Pay. Date : 2014-04-25
DMF Number : 23889
Submission : 2010-06-15
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2019-01-09
Pay. Date : 2018-11-27
DMF Number : 33373
Submission : 2018-11-28
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2015-10-21
Pay. Date : 2015-09-08
DMF Number : 22926
Submission : 2009-07-08
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2021-125 - Rev 00
Status : Valid
Issue Date : 2022-04-01
Type : Chemical
Substance Number : 2422

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2021-350 - Rev 01
Status : Valid
Issue Date : 2023-05-26
Type : Chemical
Substance Number : 2422

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 2022-488 - Rev 00
Status : Valid
Issue Date : 2024-03-07
Type : Chemical
Substance Number : 2422

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 2022-289 - Rev 00
Status : Valid
Issue Date : 2024-04-09
Type : Chemical
Substance Number : 2422

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Oseltamivir Phosphate, Route Code OMPB
Certificate Number : R0-CEP 2022-347 - Rev 00
Status : Valid
Issue Date : 2022-12-07
Type : Chemical
Substance Number : 2422

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2019-313 - Rev 01
Status : Valid
Issue Date : 2021-12-06
Type : Chemical
Substance Number : 2422

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2020-122 - Rev 01
Status : Valid
Issue Date : 2023-05-25
Type : Chemical
Substance Number : 2422

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 2012-067 - Rev 02
Status : Valid
Issue Date : 2023-10-24
Type : Chemical
Substance Number : 2422

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2021-033 - Rev 00
Status : Valid
Issue Date : 2022-07-05
Type : Chemical
Substance Number : 2422

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 2015-348 - Rev 02
Status : Valid
Issue Date : 2024-03-28
Type : Chemical
Substance Number : 2422

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] Registration Number : 304MF10109
Registrant's Address : Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400...
Initial Date of Registration : 2022-08-03
Latest Date of Registration : 2022-08-03

Registration Number : 302MF10152
Registrant's Address : 500, Sinnae-ro, Geumwang-eup, Eumseong-gun, Chungcheongbuk-do, Korea
Initial Date of Registration : 2020-12-15
Latest Date of Registration : 2020-12-15

Registration Number : 229MF10042
Registrant's Address : Plot No: C-24, Sanath Nagar Industrial Estate, Sanath Nagar, Hyderabad, Telangana, In...
Initial Date of Registration : 2017-02-15
Latest Date of Registration : 2023-12-13

Registration Number : 305MF10097
Registrant's Address : No 120 A&B, 36, 120P & 121, Industrial Area, Baikampady, New Mangalore - 575011, Karn...
Initial Date of Registration : 2023-08-22
Latest Date of Registration : 2023-08-22

Registration Number : 228MF10175
Registrant's Address : Plot No. 564/A/22, Road No. 92, Jubilee Hills, Hyderabad-500096, Telangana, India
Initial Date of Registration : 2016-08-29
Latest Date of Registration : 2019-06-18

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Synnat Pharma is one of the leading active pharmaceutical ingredients and intermediates manufacturers.
Oseltamivir Phosphate BP/IP/USP/Ph. Eur.
Date of Issue : 2024-05-22
Valid Till : 2027-02-07
Written Confirmation Number : WC-0301
Address of the Firm : Plot No. 60A, Jawaharlal Nehru Pharma City, Parawada Mandal, Anakapalli District...
Date of Issue : 2024-07-18
Valid Till : 2027-06-07
Written Confirmation Number : WC-0317
Address of the Firm : Plot No. 43 & 44, IDA Phase-ll, Pashamylaram, Pashamylaram(V), Patancheru (M), S...

Oseltamivir Phosphate BP/USP/PH. Eur
Date of Issue : 2025-06-20
Valid Till : 2028-07-02
Written Confirmation Number : WC-0140
Address of the Firm : D-22, M.I.D.C, Industrial Area,Kurkumbh, Taluka

Date of Issue : 2024-02-19
Valid Till : 2027-02-18
Written Confirmation Number : WC-0578
Address of the Firm : Sy.No.405 & 408, Veliminedu (Village), Chityal (Mandal), Nalgonda District - 508...

Oseltamivir Phosphate USP/Ph.Eur.
Date of Issue : 2025-09-03
Valid Till : 2028-08-08
Written Confirmation Number : WC-0041
Address of the Firm : Unit-I, Sy. No. 10, I.D.A, Gaddapotharam (V), Jinnaram (M), Sangareddy District,...

Oseltamivir Phosphate USP/Ph.Eur
Date of Issue : 2023-10-25
Valid Till : 2026-01-07
Written Confirmation Number : WC-471
Address of the Firm : Plot no.23A & 23B, Atchutapuram, Lalam Koduru (Village), Rambilli (Mandal), Visa...

Oseltamivir Phosphate USP/Ph. Eur
Date of Issue : 2023-10-25
Valid Till : 2023-12-18
Written Confirmation Number : WC-0471
Address of the Firm : Plotno.23A&23B,Atchutapuram, LalamKoduru(Village), Rambilli (Mandal), Visakhapat...

Date of Issue : 2024-08-04
Valid Till : 2026-03-22
Written Confirmation Number : WC-0395
Address of the Firm : Plot No. 18, Jawaharlal Nehru Pharma City, Parawada Mandal, Anakapalli District ...

Oseltamivir Phosphate USP/Ph. Eur
Date of Issue : 2025-09-08
Valid Till : 2028-08-15
Written Confirmation Number : WC-0022
Address of the Firm : Plot No. 182 to 186, 192-A and 193 to 197 & 212/A,B,C,D Phase-ll, IDA, Pashamyla...

Date of Issue : 2025-09-24
Valid Till : 2028-08-08
Written Confirmation Number : WC-0383
Address of the Firm : Unit-ll, Sy No * Parts of 454,455,457,458 & 459 Chandampet-Village, Shankarampet...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Registrant Name : Otran Korea Co., Ltd.
Registration Date : 2021-05-18
Registration Number : 20210518-209-J-995
Manufacturer Name : BrightGene Fine Chemical Co....
Manufacturer Address : No.22 Binjiang South Road, Taixing Economic Development Zone, Taizhou City, Jiangsu, ...

Registrant Name : Ace Biopharm Co., Ltd.
Registration Date : 2022-06-14
Registration Number : 20220614-209-J-1315
Manufacturer Name : Cdymax (India) Pharma Privat...
Manufacturer Address : No. 116/117, KIADB Industrial Area, Jigani, Bangalore-560105. Karnataka, India

Registrant Name : UNUST Co., Ltd.
Registration Date : 2021-10-19
Registration Number : 20211019-209-J-1125
Manufacturer Name : Cipla Limited
Manufacturer Address : Plot No. D-22, MIDC Industrial Area, Kurkumbh, Taluka Daund, Pune 413802 Maharashtra ...

Registrant Name : Roche Korea Co., Ltd.
Registration Date : 2022-04-22
Registration Number : 20220422-209-J-1274
Manufacturer Name : F. Hoffmann-La Roche AG
Manufacturer Address : Grenzacherstrasse 124, 4070 Basel, Switzerland

Registrant Name : Iksoo Pharmaceutical Co., Ltd.
Registration Date : 2025-04-21
Registration Number : 20250421-209-J-1848
Manufacturer Name : Ruyuan HEC Pharma Co., Ltd.
Manufacturer Address : Xiaba Development Zone, Ruyuan County, Shaoguan City, 512721, Guangdong Province, Chi...

Registrant Name : Lee Sung International Co., Ltd.
Registration Date : 2022-12-05
Registration Number : 20221205-209-J-1417
Manufacturer Name : Hetero Labs Limited Unit-I
Manufacturer Address : Survey No.10, IDA, Gaddapotharam Village, Jinnaram Mandal, SangaReddy District.-50231...

Registrant Name : Inistest Co., Ltd.
Registration Date : 2022-09-08
Registration Number : 20220908-209-J-1361
Manufacturer Name : Inistest Co., Ltd.
Manufacturer Address : 500 Shinnae-ro, Geumwang-eup, Eumseong-gun, Chungcheongbuk-do

Registrant Name : Sungwoo Biopharm Co., Ltd.
Registration Date : 2021-02-05
Registration Number : 20210205-209-J-833
Manufacturer Name : Sinopep-Allsino Biopharmaceu...
Manufacturer Address : No. 28, Linpu Road, Economic & Technological Development Zone, Lianyungang, Jiangsu P...

Registrant Name : Roche Korea Co., Ltd.
Registration Date : 2022-04-26
Registration Number : 20220426-209-J-1279
Manufacturer Name : Patheon API Inc.
Manufacturer Address : 6173 East Old Marion Highway, Florence, South Carolina 29506-9330, United States

Registrant Name : Masung LS Co., Ltd.
Registration Date : 2020-07-02
Registration Number : 20190718-209-J-179(5)
Manufacturer Name : Solara Active Pharma Science...
Manufacturer Address : 120 A&B, 120P & 121, Industrial Area Baikampady New Mangalore – 575 011, India

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Synnat Pharma is one of the leading active pharmaceutical ingredients and intermediates manufacturers.
About the Company : Synnat Pharma is a fast-growing pharmaceutical company dedicated to the identification, development, production and distribution of potent phytochemicals and botanical extracts. AP...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
Gonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.
About the Company : Gonane Pharma, is a contract pharmaceutical company located in Gujarat, India, specializing in the manufacturing and marketing of Corticosteroids, Hormones, Antivirals, and Oncolog...
About the Company : Jai Radhe Sales was founded in 1999 as an out-of-the-box distribution firm specializing in the global supply of high-quality pharmaceutical ingredients. The firm provides complete ...
About the Company : HRV Pharma is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
About the Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological API...
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
About the Company : Tenatra International was established as a proprietorship firm in 1999. It got off to a very good start, supporting clients in the United States, Mexico and Europe. As business opp...
About the Company : Aspire group was established in the year 2000 with a motto of quality drug for better health of all. In its journey till date, aspire has developed enormous reputation, consistent ...

About the Company : Cipla is a global pharmaceutical company whose goal is ensuring no patient shall be denied access to high quality & affordable medicine and support. Mission: Cipla’s mission i...

About the Company : MANA PHARMA, S.L. is a Spanish Pharmaceutical Company, with Authorization as a Wholesale Pharmaceutical Distribution Entity of Medicines for Human Use as well as a Certificate of G...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
ZX-7101A is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): ZX-7101A,Oseltamivir Phosphate
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 28, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ZX-7101A,Oseltamivir Phosphate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ZX-7101A is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 28, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
GP681 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): GP681,Rosuvastatin Calcium,Digoxin,Itraconazole,Oseltamivir Phosphate
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 29, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : GP681,Rosuvastatin Calcium,Digoxin,Itraconazole,Oseltamivir Phosphate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GP681 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 29, 2023

Details:
Baloxavir Marboxil is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Influenza, Human.
Lead Product(s): Baloxavir Marboxil,Oseltamivir Phosphate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous
Sponsor: Genentech
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 27, 2021

Lead Product(s) : Baloxavir Marboxil,Oseltamivir Phosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Baloxavir Marboxil is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Influenza, Human.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 27, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
ZSP1273 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): ZSP1273,Oseltamivir Phosphate
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 04, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ZSP1273,Oseltamivir Phosphate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir
Details : ZSP1273 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 04, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Oseltamivir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Oseltamivir Phosphate,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 19, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Oseltamivir Phosphate,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioavailability of Oseltamivir Phosphate 75 mg With Regards to Reference Product
Details : Oseltamivir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 19, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The venture loan is intended to support Immunic’s ongoing phase 2 CALVID-1 trial of its lead asset, IMU-838, in patients with moderate coronavirus disease 2019 (COVID-19).
Lead Product(s): Vidofludimus Calcium,Oseltamivir Phosphate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: European Investment Bank
Deal Size: $28.6 million Upfront Cash: Undisclosed
Deal Type: Funding October 20, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vidofludimus Calcium,Oseltamivir Phosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : European Investment Bank
Deal Size : $28.6 million
Deal Type : Funding
EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVI...
Details : The venture loan is intended to support Immunic’s ongoing phase 2 CALVID-1 trial of its lead asset, IMU-838, in patients with moderate coronavirus disease 2019 (COVID-19).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 20, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Oseltamivir Phosphate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Lead Product(s): Oseltamivir Phosphate,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 02, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Oseltamivir Phosphate,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oseltamivir Phosphate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 02, 2020

Details:
IMU-838 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Lead Product(s): IMU-838,Oseltamivir Phosphate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Immunic Therapeutics | University of Warwick | MODEPHARMA
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 18, 2020

Lead Product(s) : IMU-838,Oseltamivir Phosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Immunic Therapeutics | University of Warwick | MODEPHARMA
Deal Size : Inapplicable
Deal Type : Inapplicable
IMU-838 and Oseltamivir in the Treatment of COVID-19
Details : IMU-838 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 18, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The IONIC trial is a prospective, randomized, parallel-group, open-label phase 2b study, designed to evaluate efficacy & safety of IMU-838 in combination with the neuraminidase inhibitor, Oseltamivir, in approximately 120 adult COVID-19 patients.
Lead Product(s): Vidofludimus Calcium,Oseltamivir Phosphate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 27, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vidofludimus Calcium,Oseltamivir Phosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The IONIC trial is a prospective, randomized, parallel-group, open-label phase 2b study, designed to evaluate efficacy & safety of IMU-838 in combination with the neuraminidase inhibitor, Oseltamivir, in approximately 120 adult COVID-19 patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 27, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Corticosteroid is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Severe Acute Respiratory Syndrome.
Lead Product(s):
Corticosteroid,Hydroxychloroquine Sulphate,Lopinavir,Ritonavir,Azithromycin,Convalescent Plasma,Tocilizumab,Immunoglobulin,Aspirin,Colchicine,Baricitinib,
Therapeutic Area: Pulmonary/Respiratory Diseases
Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Undisclosed Sponsor:
UK Research and Innovation | National Institute for Health Research, UK | Wellcome Trust | Bill & Melinda Gates Foundation | DFID UK | Health Data Research UK | Medical Research Council Population Health Research Unit | NIHR Clinical Trials Unit Support F
Deal Size: Inapplicable
Upfront Cash: Inapplicable
Deal Type: Inapplicable
May 11, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) :
Corticosteroid,Hydroxychloroquine Sulphate,Lopinavir,Ritonavir,Azithromycin,Convalescent Plasma,Tocilizumab,Immunoglobulin,Aspirin,Colchicine,Baricitinib,
Therapeutic Area :
Pulmonary/Respiratory Diseases Highest Development Status :
Phase III Partner/Sponsor/Collaborator :
UK Research and Innovation | National Institute for Health Research, UK | Wellcome Trust | Bill & Melinda Gates Foundation | DFID UK | Health Data Research UK | Medical Research Council Population Health Research Unit | NIHR Clinical Trials Unit Support F Deal Size : Inapplicable Deal Type : Inapplicable
Randomised Evaluation of COVID-19 Therapy
Details : Corticosteroid is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Severe Acute Respiratory Syndrome.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 11, 2020

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Oseltamivir Accord
Dosage Form : Hard Capsule
Dosage Strength : 75MG
Packaging :
Approval Date : 2023-06-19
Application Number : 88914
Regulatory Info : Authorized
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Generic
Registration Country : Turkey
Brand Name : ENFLUVIR
Dosage Form : Powder for Oral Suspension
Dosage Strength : 12MG/ML
Packaging : 52 ml Glass Bottle
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Turkey

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Norway
Brand Name : Tamiflu
Dosage Form : Powder for potion, suspension
Dosage Strength : 12 mg/ml
Packaging : Bottle of glass
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Tamiflu
Dosage Form : Capsule
Dosage Strength : 45mg
Packaging :
Approval Date : 19/09/2007
Application Number : 20070321000021
Regulatory Info : Approved
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Deregistered
Registration Country : Sweden
Brand Name : Tamiflu
Dosage Form : Powder For Oral Suspension
Dosage Strength : 12mg/ml
Packaging :
Approval Date : 20/06/2002
Application Number : 20020620000062
Regulatory Info : Deregistered
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Oseltamivir Hec Pharm
Dosage Form : Hard Capsule
Dosage Strength : 30MG
Packaging :
Approval Date : 2020-07-24
Application Number : 85275
Regulatory Info : Authorized
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Ebilfumin
Dosage Form : Capsule
Dosage Strength : 45mg
Packaging :
Approval Date : 22/05/2014
Application Number : 20130601000049
Regulatory Info : Approved
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Generic US CTD
Registration Country : United Kingdom
Brand Name :
Dosage Form : CAPSULE
Dosage Strength : 30MG
Packaging :
Approval Date :
Application Number : 202595
Regulatory Info : Generic US CTD
Registration Country : United Kingdom

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Tamiflu
Dosage Form : Hard Capsule
Dosage Strength : 45MG
Packaging :
Approval Date : 2007-10-05
Application Number : 02222004
Regulatory Info : Authorized
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Cancelled
Registration Country : Spain
Brand Name : Oseltamivir Zentiva
Dosage Form : Hard Capsule
Dosage Strength : 45MG
Packaging :
Approval Date : 2020-05-04
Application Number : 85056
Regulatory Info : Cancelled
Registration Country : Spain

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Regulatory Info :
Registration Country : India
Brand Name : Oseltamivir Phosphate
Dosage Form : Capsule
Dosage Strength : 75MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Capsule
Dosage Strength : 75MG
Brand Name : Oseltamivir Phosphate
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name : Oseltamivir Phosphate
Dosage Form : Capsule
Dosage Strength : 30MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Capsule
Dosage Strength : 30MG
Brand Name : Oseltamivir Phosphate
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name : Oseltamivir Phosphate
Dosage Form : Capsule
Dosage Strength : 45MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Capsule
Dosage Strength : 45MG
Brand Name : Oseltamivir Phosphate
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name : Oseltamivir Phosphate
Dosage Form : Capsule
Dosage Strength : 75MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Capsule
Dosage Strength : 75MG
Brand Name : Oseltamivir Phosphate
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name : Oseltamivir Phosphate
Dosage Form : Oral Solution
Dosage Strength : 6MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Oral Solution
Dosage Strength : 6MG
Brand Name : Oseltamivir Phosphate
Approval Date :
Application Number :
Registration Country : India
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Turkey
Brand Name : ENFLUVIR
Dosage Form : Capsules
Dosage Strength : 30MG
Packaging : 10 Capsules Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Turkey

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging : 10 Capsules Blister
Regulatory Info :
Dosage : Capsules
Dosage Strength : 30MG
Brand Name : ENFLUVIR
Approval Date :
Application Number :
Registration Country : Turkey

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Hard Capsule
Dosage Strength : 45MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging :
Regulatory Info :
Dosage : Hard Capsule
Dosage Strength : 45MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : South Korea
Brand Name : Oseltami Capsule
Dosage Form : Capsule
Dosage Strength : 75MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : South Korea

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging :
Regulatory Info :
Dosage : Capsule
Dosage Strength : 75MG
Brand Name : Oseltami Capsule
Approval Date :
Application Number :
Registration Country : South Korea

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Iran
Brand Name : OSELTAMIVIR CAPSULE OR...
Dosage Form : Capsule
Dosage Strength : 75MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging :
Regulatory Info :
Dosage : Capsule
Dosage Strength : 75MG
Brand Name : OSELTAMIVIR CAPSULE OR...
Approval Date :
Application Number :
Registration Country : Iran

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Egypt
Brand Name : Taminil - N
Dosage Form : Capsule
Dosage Strength : 75MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Egypt

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging :
Regulatory Info :
Dosage : Capsule
Dosage Strength : 75MG
Brand Name : Taminil - N
Approval Date :
Application Number :
Registration Country : Egypt

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
37
PharmaCompass offers a list of Oseltamivir Phosphate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Oseltamivir Phosphate manufacturer or Oseltamivir Phosphate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Oseltamivir Phosphate manufacturer or Oseltamivir Phosphate supplier.
PharmaCompass also assists you with knowing the Oseltamivir Phosphate API Price utilized in the formulation of products. Oseltamivir Phosphate API Price is not always fixed or binding as the Oseltamivir Phosphate Price is obtained through a variety of data sources. The Oseltamivir Phosphate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Tamiflu manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tamiflu, including repackagers and relabelers. The FDA regulates Tamiflu manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tamiflu API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Tamiflu manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Tamiflu supplier is an individual or a company that provides Tamiflu active pharmaceutical ingredient (API) or Tamiflu finished formulations upon request. The Tamiflu suppliers may include Tamiflu API manufacturers, exporters, distributors and traders.
click here to find a list of Tamiflu suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Tamiflu DMF (Drug Master File) is a document detailing the whole manufacturing process of Tamiflu active pharmaceutical ingredient (API) in detail. Different forms of Tamiflu DMFs exist exist since differing nations have different regulations, such as Tamiflu USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Tamiflu DMF submitted to regulatory agencies in the US is known as a USDMF. Tamiflu USDMF includes data on Tamiflu's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tamiflu USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Tamiflu suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Tamiflu Drug Master File in Japan (Tamiflu JDMF) empowers Tamiflu API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Tamiflu JDMF during the approval evaluation for pharmaceutical products. At the time of Tamiflu JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Tamiflu suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Tamiflu Drug Master File in Korea (Tamiflu KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Tamiflu. The MFDS reviews the Tamiflu KDMF as part of the drug registration process and uses the information provided in the Tamiflu KDMF to evaluate the safety and efficacy of the drug.
After submitting a Tamiflu KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Tamiflu API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Tamiflu suppliers with KDMF on PharmaCompass.
A Tamiflu CEP of the European Pharmacopoeia monograph is often referred to as a Tamiflu Certificate of Suitability (COS). The purpose of a Tamiflu CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Tamiflu EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Tamiflu to their clients by showing that a Tamiflu CEP has been issued for it. The manufacturer submits a Tamiflu CEP (COS) as part of the market authorization procedure, and it takes on the role of a Tamiflu CEP holder for the record. Additionally, the data presented in the Tamiflu CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Tamiflu DMF.
A Tamiflu CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Tamiflu CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Tamiflu suppliers with CEP (COS) on PharmaCompass.
A Tamiflu written confirmation (Tamiflu WC) is an official document issued by a regulatory agency to a Tamiflu manufacturer, verifying that the manufacturing facility of a Tamiflu active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Tamiflu APIs or Tamiflu finished pharmaceutical products to another nation, regulatory agencies frequently require a Tamiflu WC (written confirmation) as part of the regulatory process.
click here to find a list of Tamiflu suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tamiflu as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Tamiflu API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Tamiflu as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Tamiflu and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tamiflu NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Tamiflu suppliers with NDC on PharmaCompass.
Tamiflu Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tamiflu GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tamiflu GMP manufacturer or Tamiflu GMP API supplier for your needs.
A Tamiflu CoA (Certificate of Analysis) is a formal document that attests to Tamiflu's compliance with Tamiflu specifications and serves as a tool for batch-level quality control.
Tamiflu CoA mostly includes findings from lab analyses of a specific batch. For each Tamiflu CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tamiflu may be tested according to a variety of international standards, such as European Pharmacopoeia (Tamiflu EP), Tamiflu JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tamiflu USP).